We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA CITES POTENTIAL IMPACT IN APPEALING PAXIL DECISION
FDA CITES POTENTIAL IMPACT IN APPEALING PAXIL DECISION
February 13, 2004
Citing the potential far-reaching impact of the decision, the FDA said last week that it will appeal a court ruling overturning the agency’s decision to grant shared 180-day exclusivity to several generic firms seeking to market a version of GlaxoSmithKline’s depression drug Paxil (paroxetine HCl).